Payment overview · 2025
General Payments
$1,592.21
26 reported records · 14 companies
Healthcare provider profile · identity verified
Eli S Djebiyan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ENGLEWOOD, NJ · NPI 1841215969
Verified facts
What the public records show
CMS Open Payments records show Eli S Djebiyan, MD received $1,592.21 in general payments during 2025 across 26 reported records.
PROTEGA PHARMACEUTIALS INC accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEFLARO as an associated drug or biological on 11895 records involving 6021 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Teflaro by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1336 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $712.53 | 44.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $414.44 | 26.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.98 | 7.8% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $87.26 | 5.5% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $36.06 | 2.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.72 | 2.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.49 | 2.2% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.54 | 1.9% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.36 | 1.9% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.45 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.82 | 1.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$17.47 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.63 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.46 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $979.71 | 25 |
| Honoraria | $612.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $712.53 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $414.44 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $53.31 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1336 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | TEFLARO open payments reported associated product |
CMS Open Payments — General Payments 11895 supporting records · 6021 recipient NPIs · example record 1201352826 |
Teflaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1336 | 110 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2028 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 1476 | 173 |
| Eliquis | Apixaban | 1336 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1275 | 147 |
| Losartan Potassium | Losartan Potassium | 1047 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 999 | 122 |
| Furosemide | Furosemide | 996 | 130 |
| Mirtazapine | Mirtazapine | 983 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 806 | 82 |
| Gabapentin | Gabapentin | 697 | 75 |
| Metformin Hcl | Metformin Hcl | 653 | 113 |
| Famotidine | Famotidine | 603 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 594 | 88 |
| Divalproex Sodium | Divalproex Sodium | 591 | 59 |
| Lisinopril | Lisinopril | 520 | 60 |
| Simvastatin | Simvastatin | 516 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 491 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 480 | 60 |
| Potassium Chloride | Potassium Chloride | 479 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 446 | 60 |
| Donepezil Hcl | Donepezil Hcl | 416 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 410 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 403 | 40 |
| Carvedilol | Carvedilol | 390 | 44 |
| Omeprazole | Omeprazole | 373 | 57 |
| Levetiracetam | Levetiracetam | 366 | 39 |
| Sertraline Hcl | Sertraline Hcl | 361 | 38 |
| Alprazolam | Alprazolam | 345 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 56 |
| Risperidone | Risperidone | 285 | 29 |
| Xarelto | Rivaroxaban | 260 | 24 |
| Baclofen | Baclofen | 246 | 25 |
| Spironolactone | Spironolactone | 244 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 224 | 36 |
| Montelukast Sodium | Montelukast Sodium | 216 | 29 |
| Meloxicam | Meloxicam | 195 | 40 |
| Sucralfate | Sucralfate | 188 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 32 |
| Midodrine Hcl | Midodrine Hcl | 183 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 181 | 69 |
| Alendronate Sodium | Alendronate Sodium | 180 | 22 |
| Trazodone Hcl | Trazodone Hcl | 180 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 41 |
| Propranolol Hcl | Propranolol Hcl | 172 | suppressed |
| Carbamazepine | Carbamazepine | 169 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 169 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 167 | 31 |
| Atenolol | Atenolol | 164 | 19 |
| Clonidine Hcl | Clonidine Hcl | 164 | 20 |
| Lactulose | Lactulose | 163 | 36 |
| Prednisone | Prednisone | 161 | 33 |
| Glimepiride | Glimepiride | 156 | 26 |
| Finasteride | Finasteride | 154 | 26 |
| Latanoprost | Latanoprost | 145 | 33 |
| Lorazepam | Lorazepam | 145 | 40 |
| Warfarin Sodium | Warfarin Sodium | 140 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 138 | 42 |
| Digoxin | Digoxin | 136 | suppressed |
| Clonazepam | Clonazepam | 134 | 28 |
| Sevelamer Carbonate | Sevelamer Carbonate | 133 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 123 | 18 |
| Topiramate | Topiramate | 123 | suppressed |
| Jardiance | Empagliflozin | 122 | 20 |
| Entresto | Sacubitril/Valsartan | 121 | 12 |
| Olanzapine | Olanzapine | 119 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 24 |
| Januvia | Sitagliptin Phosphate | 113 | 16 |
| Ezetimibe | Ezetimibe | 109 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 107 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 106 | 21 |
| Ibuprofen | Ibuprofen | 104 | 26 |
| Memantine Hcl | Memantine Hcl | 103 | 15 |
| Tramadol Hcl | Tramadol Hcl | 102 | 37 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 101 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 97 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 94 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 94 | 11 |
| Diazepam | Diazepam | 92 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 91 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 88 | 14 |
| Promethazine Hcl | Promethazine Hcl | 88 | 35 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 87 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 87 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 85 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 80 | 23 |
| Glipizide | Glipizide | 80 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 79 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | suppressed |
| Ramipril | Ramipril | 71 | suppressed |
| Pregabalin | Pregabalin | 68 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Timolol Maleate | Timolol Maleate | 63 | 13 |
| Bumetanide | Bumetanide | 61 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 61 | 26 |
| Lansoprazole | Lansoprazole | 60 | suppressed |
| Linzess | Linaclotide | 60 | suppressed |
| Allopurinol | Allopurinol | 57 | 13 |
| Fentanyl | Fentanyl | 57 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | 17 |
| Lamictal | Lamotrigine | 57 | suppressed |
| Clonidine | Clonidine | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 54 | 36 |
| Velphoro | Sucroferric Oxyhydroxide | 54 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 53 | 13 |
| Nifedipine Er | Nifedipine | 53 | 15 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 11 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 51 | suppressed |
| Neomycin Sulfate | Neomycin Sulfate | 51 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 31 |
| Insulin Lispro | Insulin Lispro | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | suppressed |
| Cyclosporine | Cyclosporine | 46 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 46 | 21 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 46 | suppressed |
| Torsemide | Torsemide | 46 | 11 |
| Celecoxib | Celecoxib | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Phenobarbital | Phenobarbital | 42 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 40 | 26 |
| Dalfampridine Er | Dalfampridine | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | 20 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Nystatin | Nystatin | 40 | 26 |
| Cephalexin | Cephalexin | 39 | 27 |
| Dorzolamide Hcl | Dorzolamide Hcl | 38 | suppressed |
| Budesonide | Budesonide | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 19 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 37 | suppressed |
| Depakote | Divalproex Sodium | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 24 |
| Ozempic | Semaglutide | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 33 | 15 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 31 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Lacosamide | Lacosamide | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | 14 |
| Teflaro | Ceftaroline Fosamil Acetate | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 13 |
| Nyamyc | Nystatin | 29 | 14 |
| Repaglinide | Repaglinide | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 15 |
| Humalog | Insulin Lispro | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 27 | suppressed |
| Mercaptopurine | Mercaptopurine | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 26 | 14 |
| Loperamide | Loperamide Hcl | 25 | 17 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Tegretol | Carbamazepine | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 18 |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Novolog | Insulin Aspart | 23 | suppressed |
| Lumigan | Bimatoprost | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Daptomycin | Daptomycin | 20 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 12 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Metronidazole | Metronidazole | 18 | 12 |
| Naproxen | Naproxen | 18 | suppressed |
| Nystop | Nystatin | 18 | 11 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Bystolic | Nebivolol Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Desonide | Desonide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Clobazam | Clobazam | 14 | suppressed |
| Levocarnitine | Levocarnitine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,592.21 · 26 records | PROTEGA PHARMACEUTIALS INC | Arikayce, Belbuca, ELIQUIS, EVENITY, INSPIRE, NURTEC ODT, REXULTI, ROXYBOND, TZIELD, VALTOCO, VRAYLAR, Wegovy, XIFAXAN, XTAMPZA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error